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Background
Anti-cyclic citrullinated peptide (anti-CCP) antibodies are
a highly specific serological marker for adult-onset rheu-
matoid arthritis, present early in the course of the disease,
and are a marker of erosive disease.
Objective
To assess the prevalence and clinical significance of anti-
CCP antibodies in a cohort of children with juvenile idio-
pathic arthritis (JIA).
Methods
A retrospective review of the records of children with JIA
attending a paediatric rheumatology clinic at Chris Hani
Baragwanath Hospital was undertaken. Anti-CCP anti-
bodies were tested using an enzyme linked immunoab-
sorbent assay (EliACCP).
Results
Records of 52 patients (54% males, 46% females) were
reviewed. The mean (SD) age and follow-up period were
10.69 (3.81) and 2.3 (1.7) years, respectively. The major-
ity of the children (83%) were Black. The subtypes of JIA
were as follows: systemic 21%, polyarticular 50%, oligoar-
ticular 19%, enthesitis-related arthritis 2%, psoriatic 2%
and other 6%. Anti-CCP antibodies were present in the
sera of 8 of 28 patients tested (29%). They were detected
exclusively in patients with the polyarticular subtype of
JIA. IgM RF was positive in 14 (29.17%) of the total
cohort, but not exclusively in patients with the polyartic-
ular subtype of JIA. The overall concordance between the
2 tests was fair (Kappa statistic = 0.39).
Conclusion
Anti-CCP antibodies are present in a high proportion of
patients with JIA, and in the polyarticular JIA subtype.
They appear to be a better marker of this subtype than IgM
RF. The concordance between anti-CCP antibodies and
IgM RF in our patients with JIA is fair.
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